Spyre Therapeutics, Inc.

SYRE

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001636282

SEC filings (opens in a new tab)

In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Spyre Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025 All holders in Q2 2025

13F holders of SYRE: Q2 2025 compared with Q3 2025
Measure	Q2 2025	Of which not filed for Q3 2025	Q3 2025	Change
Holders	129	1	137	+9
Shares	63.6M	19.4K	64.3M	+693.4K (+1.1%)
Value	$952.6M	$290.9K	$1.08B	+$125.3M (+13.2%)

1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Spyre Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to SYRE in Q3 2025
Institution	Shares	Value	% of portfolio
TCG Crossover Management, LLC	1,100,582	$18.4M	0.91%
Millennium Management LLC	408,199	$6.84M	0.01%
Parkman Healthcare Partners LLC	200,753	$3.36M	0.37%
Jane Street Group, LLC	96,057	$1.61M	0.00%
Dimensional Fund Advisors LP	84,216	$1.41M	0.00%
Schonfeld Strategic Advisors LLC	81,474	$1.37M	0.01%
Opaleye Management Inc.	65,000	$1.09M	0.15%
DLD Asset Management, LP	30,000	$502.8K	0.06%
Jump Financial, LLC	27,100	$454.2K	0.01%
Optimize Financial Inc	24,967	$418.4K	0.22%
Susquehanna Portfolio Strategies, LLC	21,739	$364.3K	0.01%
Quadrature Capital Ltd	19,366	$324.8K	0.00%
Virginia Retirement Systems Et Al	18,500	$310.1K	0.00%
Los Angeles Capital Management LLC	18,172	$304.6K	0.00%
Dark Forest Capital Management LP	14,733	$246.9K	0.01%
DRW Securities, LLC	11,475	$190.2K	0.01%
Optiver Holding B.V.	500	$8.38K	0.00%
Rockefeller Capital Management L.P.	401	$6.72K	0.00%
SRS Capital Advisors, Inc.	121	$2.03K	0.00%
The PNC Financial Services Group, Inc.	86	$1.44K	0.00%
Farther Finance Advisors, LLC	10	$168	0.00%
Comerica Bank	5	$84	0.00%

Sold out (13)

Institutions that held Spyre Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of SYRE in Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Adage Capital Partners GP, L.L.C.	610,200	$9.13M
Deep Track Capital, LP	219,015	$3.28M
Capitolis Liquid Global Markets LLC	183,000	$2.74M
Foresite Capital Management VI LLC	70,000	$1.05M
Susquehanna International Group, LLP	59,816	$895.4K
Renaissance Technologies LLC	30,936	$463.1K
Natixis	20,040	$354.9K
Voya Investment Management LLC	13,589	$203.4K
Man Group plc	10,843	$162.3K
Skopos Labs, Inc.	520	$7.79K
Simplex Trading, LLC	145	$2.00K
Caitong International Asset Management Co., Ltd	102	$1.53K
Raymond James Financial Inc	16	$240

Not filed for Q3 2025 yet (1)

Institutions that held Spyre Therapeutics, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SYRE in Q2 2025 that haven't filed for Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
NBW Capital LLC	19,430	$290.9K